Novo leads early in oral obesity drugs, while Lilly counters with a strong injectable franchise and an oral pill nearing approval.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Novo Nordisk Vs Eli Lilly: Which Big Pharma Stock Has More Upside This Year Amid Earnings Season?
Novo leads early in oral obesity drugs, while Lilly counters with a strong injectable franchise and an oral pill nearing approval.